Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Inhibitory metabolic drug interactions with newer psychotropic drugs: inclusion in package inserts and influences of concurrence in drug interaction screening software.

Boyce RD, Collins C, Clayton M, Kloke J, Horn JR.

Ann Pharmacother. 2012 Oct;46(10):1287-98. doi: 10.1345/aph.1R150.

PMID:
23032655
2.

Evaluation of frequently used drug interaction screening programs.

Vonbach P, Dubied A, Krähenbühl S, Beer JH.

Pharm World Sci. 2008 Aug;30(4):367-74. doi: 10.1007/s11096-008-9191-x.

PMID:
18415695
3.

Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.

Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C.

Am J Geriatr Pharmacother. 2011 Dec;9(6):461-70. doi: 10.1016/j.amjopharm.2011.09.006.

PMID:
22019006
4.

Clinically relevant drug interactions between anticancer drugs and psychotropic agents.

Yap KY, Tay WL, Chui WK, Chan A.

Eur J Cancer Care (Engl). 2011 Jan;20(1):6-32. doi: 10.1111/j.1365-2354.2009.01113.x. Review.

PMID:
20030690
5.

Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI.

Yap KY, Chui WK, Chan A; Onco-Informatics (onco-informatics.com) Group..

Inform Health Soc Care. 2011 Sep;36(3):132-46. doi: 10.3109/17538157.2011.584996.

PMID:
21848450
6.

An evaluation of the completeness of drug-drug interaction-related information in package inserts.

Ng GQ, Sklar GE, Chng HT.

Eur J Clin Pharmacol. 2017 Feb;73(2):165-174. doi: 10.1007/s00228-016-2151-9.

PMID:
27796467
7.

An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.

van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.

Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009. Review.

PMID:
19808132
8.

Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan.

Ereshefsky L.

CNS Spectr. 2009 Aug;14(8 Suppl Q and A Forum):1-8.

PMID:
20085108
9.
10.

Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.

Gagne JJ, Maio V, Rabinowitz C.

J Clin Pharm Ther. 2008 Apr;33(2):141-51. doi: 10.1111/j.1365-2710.2007.00891.x.

PMID:
18315779
11.

Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.

Dechanont S, Maphanta S, Butthum B, Kongkaew C.

Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97. doi: 10.1002/pds.3592. Review.

PMID:
24616171
12.

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.

Wong CM, Ko Y, Chan A.

Ann Pharmacother. 2008 Dec;42(12):1737-48. doi: 10.1345/aph.1L255. Review.

PMID:
19033481
13.

Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians.

Chan A, Yap KY, Koh D, Low XH, Cheung YT; Onco-Informatics (onco-informatics.com) Group..

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):939-47. doi: 10.1002/pds.2167.

PMID:
21732473
14.

The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.

Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL.

Eur J Clin Pharmacol. 2012 May;68(5):767-75. doi: 10.1007/s00228-011-1156-7.

PMID:
22116460
15.

Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.

Boyce RD, Handler SM, Karp JF, Hanlon JT.

Am J Geriatr Pharmacother. 2012 Apr;10(2):139-50. doi: 10.1016/j.amjopharm.2012.01.001. Review.

16.

A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.

Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R.

J Clin Pharm Ther. 2005 Feb;30(1):21-37.

PMID:
15659001
17.

Potential determinants of prescribers' drug-drug interaction knowledge.

Ko Y, Malone DC, D'Agostino JV, Skrepnek GH, Armstrong EP, Brown M, Woosley RL.

Res Social Adm Pharm. 2008 Dec;4(4):355-66. doi: 10.1016/j.sapharm.2007.10.004.

PMID:
19064242
18.

[Improvement of package insert CYP information for prescription drugs marketed in Japan].

Hirata-Koizumi M, Saito M, Urano T, Miyake S, Hasegawa R.

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2005;(123):12-8. Japanese.

PMID:
16541745
19.

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists.

Chan A, Tan SH, Wong CM, Yap KY, Ko Y.

Clin Ther. 2009;31 Pt 2:2379-86. doi: 10.1016/j.clinthera.2009.11.008.

PMID:
20110047
20.

Evaluation of drug-drug interaction screening software combined with pharmacist intervention.

Moura CS, Prado NM, Belo NO, Acurcio FA.

Int J Clin Pharm. 2012 Aug;34(4):547-52. doi: 10.1007/s11096-012-9642-2.

PMID:
22535491

Supplemental Content

Support Center